Novo Nordisk introduces updated Rybelsus® tablet formulation in Canada for adults living with type 2 diabetes
Rybelsus® (semaglutide tablets) is the first and only GLP-1 tablet approved in Canada for adults with type 2…
Novo Nordisk Introduces Extra Savings for Canadians Who Choose Ozempic®
MISSISSAUGA, ON, May 26, 2026 /CNW/ – Novo Nordisk Canada is announcing that effective Friday, May 29, 2026,…
Health Canada approves Ozempic® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease Français
Ozempic® is the first-and-only medication indicated for both the once-weekly treatment of adult patients with type 2 diabetes…